SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Arosio M.)
 

Search: WFRF:(Arosio M.) > (2015-2019) > Uppsala University > Phage display and k...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication

Munke, Anna (author)
Uppsala universitet,Molekylär biofysik,Lund Univ, Chem Ctr, Dept Biochem & Struct Biol, SE-22100 Lund, Sweden,Lund University
Persson, Jonas (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,Lund Univ, Chem Ctr, Dept Biochem & Struct Biol, SE-22100 Lund, Sweden,Lund University,University of Cambridge
Weiffert, Tanja (author)
Lund University,Lunds universitet,Biokemi och Strukturbiologi,Centrum för Molekylär Proteinvetenskap,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Biochemistry and Structural Biology,Center for Molecular Protein Science,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH
show more...
De Genst, Erwin (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.; Astra Zeneca, Innovat Med, Discovery Sci, Cambridge CB4 0WG, England,University of Cambridge
Meisl, Georg (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England,University of Cambridge
Arosio, Paolo (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.; ETH, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland,University of Cambridge
Carnerup, Anna (author)
Lund University,Lunds universitet,Fysikalisk kemi,Enheten för fysikalisk och teoretisk kemi,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Physical Chemistry,Physical and theoretical chemistry,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH
Dobson, Christopher M. (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England,University of Cambridge
Vendruscolo, Michele (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England,University of Cambridge
Knowles, Tuomas P. J. (author)
Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.; Univ Cambridge, Dept Phys, Cavendish Lab, Cambridge CB3 0HE, England
Linse, Sara (author)
Lund University,Lunds universitet,Biokemi och Strukturbiologi,Centrum för Molekylär Proteinvetenskap,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Biochemistry and Structural Biology,Center for Molecular Protein Science,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH
show less...
 (creator_code:org_t)
2017-06-05
2017
English.
In: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 114:25, s. 6444-6449
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The aggregation of the amyloid β peptide (Aβ) into amyloid fibrils is a defining characteristic of Alzheimer’s disease. Because of the complexity of this aggregation process, effective therapeutic inhibitors will need to target the specific microscopic steps that lead to the production of neurotoxic species. We introduce a strategy for generating fibril-specific antibodies that selectively suppress fibril-dependent secondary nucleation of the 42-residue form of Aβ (Aβ42). We target this step because it has been shown to produce the majority of neurotoxic species during aggregation of Aβ42. Starting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach that we describe includes (i) selection of scFvs with high affinity for Aβ42 fibrils after removal of scFvs that bind Aβ42 in its monomeric form; (ii) ranking, by surface plasmon resonance affinity measurements, of the resulting candidate scFvs that bind to the Aβ42 fibrils; and (iii) kinetic screening and analysis to find the scFvs that inhibit selectively the fibril-catalyzed secondary nucleation process in Aβ42 aggregation. By applying this approach, we have identified four scFvs that inhibit specifically the fibril-dependent secondary nucleation process. Our method also makes it possible to discard antibodies that inhibit elongation, an important factor because the suppression of elongation does not target directly the production of toxic oligomers and may even lead to its increase. On the basis of our results, we suggest that the method described here could form the basis for rationally designed immunotherapy strategies to combat Alzheimer’s and related neurodegenerative diseases.

Subject headings

NATURVETENSKAP  -- Kemi -- Fysikalisk kemi (hsv//swe)
NATURAL SCIENCES  -- Chemical Sciences -- Physical Chemistry (hsv//eng)
NATURVETENSKAP  -- Biologi -- Biofysik (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biophysics (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Läkemedelskemi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medicinal Chemistry (hsv//eng)
NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

Alzheimer
antibody
inhibitor
drug development
self-assembly
Alzheimer
Antibody
Drug development
Inhibitor
Self-assembly

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view